Trevi Therapeutics(TRVI)
NEW HAVEN, CT
BiotechnologyFocus: Small Molecules
Trevi Therapeutics is a life sciences company focused on Small Molecules.
UnknownRespiratoryDermatologyNeurology
Funding Stage
PUBLIC
Open Jobs
6
Pipeline & Clinical Trials
Exoskeleton-Assisted Gait Training
Severe StrokeClinical Trials (1)
NCT03395717Stroke Rehabilitation With Exoskeleton-assisted Gait.
N/ANalbuphine ER
NalbuphineClinical Trials (1)
NCT04020016Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch
Phase 1Nalbuphine HCL ER
Uremic PruritusClinical Trials (1)
NCT02373215Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Phase 1NAL ER
Healthy ParticipantsClinical Trials (1)
NCT07015398A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
Phase 1Phase 1
Clinical Trials (1)
NCT07036029NAL ER IPF Respiratory Function and Safety Study
Phase 1Nalbuphine HCl solution
NalbuphineClinical Trials (1)
NCT04018664Oral Abuse Potential Study of Nalbuphine
Phase 1Phase 2
Clinical Trials (1)
NCT04030026A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
Phase 2NAL ER
Refractory Chronic CoughClinical Trials (1)
NCT05962151Refractory Chronic Cough Improvement Via NAL ER (RIVER)
Phase 2Phase 2
Clinical Trials (1)
NCT05964335Cough Reduction in IPF With Nalbuphine ER
Phase 2nalbuphine HCl ER
Uremic PruritusClinical Trials (1)
NCT02143973Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Phase 2/3nalbuphine HCl ER tablets 60 mg BID
Uremic PruritusClinical Trials (1)
NCT02143648Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Phase 2/3nalbuphine HCl ER tablets 90 mg BID
Prurigo NodularisClinical Trials (1)
NCT02174419Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Phase 2/3Nalbuphine ER Tablets
Prurigo NodularisClinical Trials (1)
NCT03497975PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Phase 2/3nalbuphine HCl ER
Prurigo NodularisClinical Trials (1)
NCT02174432Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
Phase 2/3Open Jobs (6)
CMC – Technical Operations Intern
New Haven, Connecticut
2w ago
CMC – Clinical Supplies Intern
New Haven, Connecticut
Clinical Operations2w ago
Accounting Intern
New Haven, Connecticut
Finance2w ago
Manager, Clinical Supplies
New Haven, Connecticut
Clinical Operations2w ago
Clinical Trials Lead
New Haven, Connecticut
Clinical Operations2w ago
Senior Specialist, Quality Assurance & Compliance
New Haven, Connecticut
Quality2w ago
Interview Prep Quick Facts
Portfolio: 14 clinical trials
SEC Filings: 2 available
Open Roles: 6 active jobs